Herceptin and Nail disorder - a phase IV clinical study of FDA data

Summary:

Nail disorder is reported as a side effect among people who take Herceptin (trastuzumab), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Xeloda, and have Epilepsy.

The phase IV clinical study analyzes which people have Nail disorder when taking Herceptin. It is created by eHealthMe based on reports of 41,859 people who have side effects when taking Herceptin from the FDA, and is updated regularly.

What is Herceptin?

Herceptin has active ingredients of trastuzumab. It is often used in breast cancer. eHealthMe is studying from 42,205 Herceptin users. Check the latest studies of Herceptin.

What is Nail disorder?

Nail disorder (disease of nail) is found to be associated with 738 drugs and 1,092 conditions by eHealthMe. Check the latest studies of Nail disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

41,859 people reported to have side effects when taking Herceptin.
Among them, 276 people (0.66%) have Nail disorder.

Among these 276 people:

* Approximation only. Some reports may have incomplete information.

Do you take Herceptin and have Nail disorder?

- Check whether Nail disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Herceptin:

Herceptin (42,205 reports)

Nail disorder treatments and more:

Nail disorder (9,795 reports)

How severe was Nail disorder and when was it recovered:

Nail disorder in Herceptin

Expand to all the drugs that have ingredients of trastuzumab:

Nail disorder and drugs with ingredients of trastuzumab (465 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Herceptin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nail disorder:

Nail disorder (738 drugs)

Browse all the conditions that are associated with Nail disorder:

Nail disorder (1,092 conditions)

Related publications that referenced our studies

Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D, "Bilateral macular ischemia and severe visual loss following trastuzumab therapy", Acta Oncologica, 2011 Apr .
Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D, "Bilateral macular ischemia and severe visual loss following trastuzumab therapy", Acta Oncologica, 2011 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on trastuzumab (the active ingredients of Herceptin) and Herceptin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.